PMVP PMV Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-10 16:00
Why PMVP matters now
PMV Pharmaceuticals, Inc. (PMVP) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.24 with +0.00% on the session and $66.1M in market capitalization; recent performance reads 1-month -13.74% and YTD -9.60%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-18.0M, and EPS of $-0.34. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -124.5%.
The latest indexable market news headline is "PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $5.00; recent insider activity includes BAUM CHARLES M filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.69
P/S
0.00
EV/EBITDA
-0.27
DCF Value
$0.65
FCF Yield
-124.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-69.0%
ROA
-81.1%
ROIC
-94.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-18.0M | $-0.34 |
| Q4 2025 | $0.00 | $-18.0M | $-0.34 |
| FY 2025 | $0.00 | $-77.7M | $-1.48 |
| Q3 2025 | $0.00 | $-21.1M | $-0.40 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$5.00
Target (Median)
$5.00
Target Range
$5.00 - $5.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.36
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.